List of investigational anxiolytics
This is a list of investigational anxiolytics, or anxiolytics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
Generalized anxiety disorder
- Agomelatine (AGO-178; Valdoxan) – melatonin MT1 and MT2 receptor agonist, 5-HT2C receptor antagonist
- Riluzole sublingual (BHV-0223) – undefined mechanism of action
- TGFK08AA – 5-HT1A receptor modulator
- TGW00AA (FKW00GA) – 5-HT1A receptor agonist, 5-HT2A receptor antagonist
- Vilazodone (EMD-68843, SB-659746A; Viibryd) – 5-HT1A receptor partial agonist and serotonin reuptake inhibitor
Panic disorder
- Darigabat (PF-06372865) – GABAA receptor positive allosteric modulator
- NBTX-001 (Xenon) – NMDA receptor antagonist
Post-traumatic stress disorder
- 7-Oxoprasterone (7-keto-DHEA; HBL-9001) – "immunomodulator" / undefined mechanism of action
- Acamprosate (SNC-102) – undefined mechanism of action
- BNC-210 (IW-2143) – "GABA modulator"[1] / undefined mechanism of action[2]
- Brexpiprazole (Lu AF41156, OPC-34712; Rexulti) – atypical antipsychotic / 5-HT1A, D2 and D3 receptor partial agonist and 5-HT2A, 5-HT2B, 5-HT7, α1-adrenergic, α2-adrenergic, and H1 receptor antagonist
- Iloperidone (HP-873, ILO-522; Fanapt, Fiapta, Zomaril) – atypical antipsychotic / 5-HT2A, 5-HT6, 5-HT7, D2, D3, D4, and α1-adrenergic receptor antagonist
- MDMA (Midomafetamine, 3,4-methylenedioxymethamphetamine, "ecstasy") – serotonin–norepinephrine–dopamine releasing agent and 5-HT1 and 5-HT2 receptor agonist – specifically under development as an aid to psychotherapy for post-traumatic stress disorder [3][4]
- NBTX-001 (Xenon) – NMDA receptor antagonist
- Pomaglumetad methionil (DB-103, LY-2140023) – mGluR2 and mGluR3 agonist
- Tianeptine oxalate (TNX-601) – atypical μ-opioid receptor agonist
- Verucerfont (GSK-561679, NBI-77860) – CRF1 receptor antagonist
Social anxiety disorder
- 4-Androstadienol (Aloradine; PH94B) – vomeropherine / neurosteroid
- Fluvoxamine extended release - Serotonin uptake inhibitors. [5]
- Riluzole sublingual (BHV-0223) – "glutamate modulator" / undefined mechanism of action
- TGW00AA (FKW00GA) – 5-HT1A receptor agonist, 5-HT2A receptor antagonist
- Verucerfont (GSK-561679, NBI-77860) – CRF1 receptor antagonist
- Vilazodone (EMD-68843, SB-659746A; Viibryd) – 5-HT1A receptor partial agonist and serotonin reuptake inhibitor
- JNJ-42165279 - FAAH inhibitor[6][7]
unspecified
- AVN-101 – 5-HT6 receptor antagonist
- BNC-210 (IW-2143) – "GABA modulator"[1] / undefined mechanism of action[2]
- JNJ-42165279 – FAAH inhibitor
- MP-20X – CB1 and 5-HT1A receptor modulator
- SRX-246 – vasopressin V1A receptor antagonist
See also
References
- Garakani, Amir; Murrough, James W.; Iosifescu, Dan V. (2014). "Advances in Psychopharmacology for Anxiety Disorders". FOCUS. 12 (2): 152–162. doi:10.1176/appi.focus.12.2.152. ISSN 1541-4094.
- Doggrell, S. A. (2007). Novel drugs and products in neuroscience. Drugs of the Future, 32(11), 1007-1017. https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=3853&p_IsPs=Y
- Sessa B (2017). "MDMA and PTSD treatment: "PTSD: From novel pathophysiology to innovative therapeutics"". Neurosci. Lett. 649: 176–180. doi:10.1016/j.neulet.2016.07.004. PMID 27394687.
- Philipps, Dave (29 November 2016). "F.D.A. Agrees to New Trials for Ecstasy as Relief for PTSD Patients". Retrieved 1 June 2017.
- "Fluvoxamine extended release - Beijing CoSci Med Tech - AdisInsight". adisinsight.springer.com. Retrieved 2019-08-06.
- "JNJ 42165279 - AdisInsight". adisinsight.springer.com. Retrieved 2019-03-02.
- "A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder | Clinical Research Trial Listing ( Claustrophobia ) ( NCT02432703 )". www.centerwatch.com. Retrieved 2019-03-02.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.